Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis

Journal of Neuroimmunology

Volumn 209, Issue 1-2, 2009, Pages 123-130

  Zivadinov, Robert ^a,b   Weinstock Guttman, Bianca ^b   Zorzon, Marino ^c   Uxa, Laura ^d   Serafin, Maurizia ^e   Bosco, Antonio ^c   Bratina, Alessio ^c   Maggiore, Cosimo ^c   Grop, Attilio ^c   Tommasi, Maria Antonietta ^c   Srinivasaraghavan, Bhooma ^a   Ramanathan, Murali ^b,f  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c Department of Clinical Medicine and Neurology ^*  (Italy)

^d Blood Transfusion Center   (Italy)

^e UNIVERSITY OF TRIESTE   (Italy)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

Epstein Barr virus; Gene environment interactions; HLA; MHC; Multiple sclerosis

Indexed keywords

EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; HLA A2 ANTIGEN; HLA B7 ANTIGEN; HUMORAL ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS CAPSID ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; BRAIN INJURY; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GENE LOCUS; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HLA TYPING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; BRAIN; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX;

EID: 64549161523     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.01.023     Document Type: Article

References (42)

1. Ascherio A., and Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61 (2007) 288-299
2. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernan M.A., Olek M.J., Hankinson S.E., and Hunter D.J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. Jama 286 (2001) 3083-3088
3. Ashburner J., and Friston K.J. Voxel-based morphometry-the methods. Neuroimage 11 (2000) 805-821
4. Banwell B., Krupp L., Kennedy J., Tellier R., Tenembaum S., Ness J., Belman A., Boiko A., Bykova O., Waubant E., Mah J.K., Stoian C., Kremenchutzky M., Bardini M.R., Ruggieri M., Rensel M., Hahn J., Weinstock-Guttman B., Yeh E.A., Farrell K., Freedman M., Iivanainen M., Sevon M., Bhan V., Dilenge M.E., Stephens D., and Bar-Or A. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 6 (2007) 773-781
5. Buljevac D., van Doornum G.J., Flach H.Z., Groen J., Osterhaus A.D., Hop W., van Doorn P.A., van der Meche F.G., and Hintzen R.Q. Epstein-Barr virus and disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1377-1381
6. Burt R.D., Vaughan T.L., Nisperos B., Swanson M., and Berwick M. A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in US Caucasians. Int. J. Cancer 56 (1994) 465-467
7. Carone D.A., Benedict R.H., Dwyer M.G., Cookfair D.L., Srinivasaraghavan B., Tjoa C.W., and Zivadinov R. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage 29 (2006) 505-514
8. Clatch R.J., Melvold R.W., Dal Canto M.C., Miller S.D., and Lipton H.L. The Theiler's murine encephalomyelitis virus (TMEV) model for multiple sclerosis shows a strong influence of the murine equivalents of HLA-A, B, and C. J. Neuroimmunol. 15 (1987) 121-135
9. Cohen J.I. Epstein-Barr virus infection. N. Engl. J. Med. 343 (2000) 481-492
10. De Jager P.L., Simon K.C., Munger K.L., Rioux J.D., Hafler D.A., and Ascherio A. Integrating risk factors. HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 70 (2008) 1113-1118
11. Ebers G.C., Kukay K., Bulman D.E., Sadovnick A.D., Rice G., Anderson C., Armstrong H., Cousin K., Bell R.B., Hader W., Paty D.W., Hashimoto S., Oger J., Duquette P., Warren S., Gray T., O'Connor P., Nath A., Auty A., Metz L., Francis G., Paulseth J.E., Murray T.J., Pryse-Phillips W., Nelson R., Freedman M., Brunet D., Bouchard J.P., Hinds D., and Risch N. A full genome search in multiple sclerosis. Nat. Genet. 13 (1996) 472-476
12. Fogdell-Hahn A., Ligers A., Gronning M., Hillert J., and Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55 (2000) 140-148
13. Gyodi E., Benczur M., Palffy G., Talas M., Petranyi G., Foldes I., and Hollan S.R. Association between HLA B7, DR2 and dysfunction of natural- and antibody-mediated cytotoxicity without connection with the deficient interferon production in multiple sclerosis. Hum. Immunol. 4 (1982) 209-217
14. Habek M., Brinar V.V., and Hajnsek S. The association of multiple sclerosis and Hodgkin's disease: the role of Epstein-Barr virus infection. Mult. Scler. 14 (2008) 284-287
15. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., and Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007) 851-862
16. Harbo H.F., Lie B.A., Sawcer S., Celius E.G., Dai K.Z., Oturai A., Hillert J., Lorentzen A.R., Laaksonen M., Myhr K.M., Ryder L.P., Fredrikson S., Nyland H., Sorensen P.S., Sandberg-Wollheim M., Andersen O., Svejgaard A., Edland A., Mellgren S.I., Compston A., Vartdal F., and Spurkland A. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 63 (2004) 237-247
17. Hjalgrim H., Rasmussen S., Rostgaard K., Nielsen N.M., Koch-Henriksen N., Munksgaard L., Storm H.H., and Melbye M. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J. Natl. Cancer Inst. 96 (2004) 780-784
18. Hollsberg P., Hansen H.J., and Haahr S. Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin. Exp. Immunol. 132 (2003) 137-143
19. Jarrett R.F. Viruses and Hodgkin's disease. Leukemia 7 Suppl 2 (1993) S78-82
20. Johnson A.J., Suidan G.L., McDole J., and Pirko I. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?. Int. Rev. Neurobiol. 79 (2007) 73-97
21. Landgren O., Kerstann K.F., Gridley G., Mellemkjaer L., Hemminki K., Linet M.S., and Goldin L.R. Re: Familial clustering of Hodgkin lymphoma and multiple sclerosis. J. Natl. Cancer Inst. 97 (2005) 543-544 author reply 544-545
22. Lang H.L., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L., Hjorth P., Sondergaard L., Svejgaard A., Wucherpfennig K., Stuart D.I., Bell J.I., Jones E.Y., and Fugger L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3 (2002) 940-943
23. Li D.K., Held U., Petkau J., Daumer M., Barkhof F., Fazekas F., Frank J.A., Kappos L., Miller D.H., Simon J.H., Wolinsky J.S., and Filippi M. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66 (2006) 1384-1389
24. Lindberg C., Andersen O., Vahlne A., Dalton M., and Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 10 (1991) 62-65
25. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
26. Lunemann J.D., Kamradt T., Martin R., and Munz C. Epstein-Barr virus: environmental trigger of multiple sclerosis?. J. Virol. 81 (2007) 6777-6784
27. Newell G.R. Etiology of multiple sclerosis and Hodgkin's disease. Am. J. Epidemiol. 91 (1970) 119-122
28. Nielsen T.R., Pedersen M., Rostgaard K., Frisch M., and Hjalgrim H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult. Scler. 13 (2007) 420-423
29. Nielsen T.R., Rostgaard K., Nielsen N.M., Koch-Henriksen N., Haahr S., Sorensen P.S., and Hjalgrim H. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 64 (2007) 72-75
30. Niens M., Jarrett R.F., Hepkema B., Nolte I.M., Diepstra A., Platteel M., Kouprie N., Delury C.P., Gallagher A., Visser L., Poppema S., te Meerman G.J., and van den Berg A. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 110 (2007) 3310-3315
31. Piazza A., Menozzi P., and Cavalli-Sforza L.L. Synthetic gene frequency maps of man and selective effects of climate. Proc. Natl. Acad. Sci. U. S. A. 78 (1981) 2638-2642
32. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
33. Sanfilipo M.P., Benedict R.H., Zivadinov R., and Bakshi R. Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage 22 (2004) 1732-1743
34. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Dahl D.B., Chen M., Cheng Y.J., Westra W.H., Chen C.J., Hildesheim A., Sugden B., and Ahlquist P. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 66 (2006) 7999-8006
35. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., Andreoni L., Trivedi P., Salvetti M., Faggioni A., and Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204 (2007) 2899-2912
36. Trapp B.D., Ransohoff R., and Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12 (1999) 295-302
37. Wandinger K., Jabs W., Siekhaus A., Bubel S., Trillenberg P., Wagner H., Wessel K., Kirchner H., and Hennig H. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 55 (2000) 178-184
38. Zivadinov R., Rudick R.A., De Masi R., Nasuelli D., Ukmar M., Pozzi-Mucelli R.S., Grop A., Cazzato G., and Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 (2001) 1239-1247
39. Zivadinov R., Uxa L., Zacchi T., Nasuelli D., Ukmar M., Furlan C., Pozzi-Mucelli R., Tommasi M.A., Locatelli L., Ulivi S., Bratina A., Bosco A., Grop A., Cazzato G., and Zorzon M. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J. Neurol. 250 (2003) 1099-1106
40. Zivadinov R., Nasuelli D., Tommasi M.A., Serafin M., Bratina A., Ukmar M., Pirko I., Johnson A.J., Furlan C., Pozzi-Mucelli R.S., Monti-Bragadin L., Grop A., Zambon M., Antonello R.M., Cazzato G., and Zorzon M. Positivity of cytomegalovirus antibodies predicts a better clinical and radiological outcome in multiple sclerosis patients. Neurol. Res. 28 (2006) 262-269
41. Zivadinov R., Uxa L., Bratina A., Bosco A., Srinivasaraghavan B., Minagar A., Ukmar M., Benedetto S., and Zorzon M. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int. Rev. Neurobiol. 79 (2007) 521-535
42. Zivadinov, R., Zorzon, M., Weinstock-Guttman, B., Serafin, M., Bosco, A., Bratina, A., Maggiore, C., Grop, A., Tommasi, M.A., Srinivasaraghavan, B., Ramanathan, M., in press. Epstein-Barr virus is associated with gray matter atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry (January 23, 2009, Electronic publication, PMID:19168469)